May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

Unity in-licenses UCSF protein for cognitive improvement
Unity Biotechnology Inc. (NASDAQ:UBX) licensed from the University of California San Francisco exclusive, worldwide rights to IP relating to KLA, including its use to reverse or prevent cognitive decline. KLA is a circulating factor associated with improved cognitive performance. Financial terms were not disclosed.

FDA adds OS data to Astellas' Xospata label
FDA approved an sNDA from Astellas Pharma Inc. (Tokyo:4503) to include on Xospata gilteritinib's label overall survival data from the Phase III ADMIRAL trial, in which Xospata monotherapy improved OS vs. salvage chemotherapy. FDA approved the small molecule AXL and FLT3 inhibitor in November to treat relapsed or refractory acute myelogenous leukemia with an FLT3 mutation (see "FDA Approves Astellas' Xospata in FLT-3 Positive AML")...